However, unlike NSCLC with less frequent oncogenic drivers (e.g., EGFR, ALK, MET1, and ROS1) that respond significantly to selective kinase inhibitors [2], effective therapies specifically targeting KRAS-mutant cancers remains a challenge [2, 3]. This evidence concerns the gene KRAS and cancer.